Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Bullboard Posts
Post by sammydlon May 17, 2018 2:58pm
150 Views
Post# 28047846

Massive share price gain coming.

Massive share price gain coming.Very undervalued play, shot up same time last year from 0.17 to 0.29, Q1 results in next week will be even bigger then last's year's results. 


bmoe80 wrote: Stock up, average down. Good buy in price right now. Meeting is next Thursday and Q1 results will be announced by then or on that day. From what I gather, it should be one of the best quarters, we should also be seeing some more positive numbers/contracts coming through. Last year this time stock ran up to 0.29 on the revenue growth results, hopefully we see it testing this January's highs of 0.21 and better. 

Market hasn't taken into account it's growing revenue stream over the past year, or einsteinium/cryptocurrency pontential, or potential for "Voxtel in the political arena its planned  launch in crypto contributions in the Fall of 2018.

Definitely very undervalued at current stock price, especially compared to similiar stocks like MOS which had 2017 revenues of less then $3 milliion compared to ATW's $12 million, but trades at a much higher market cap of $25 million. This stock should be trading well about the 0.30/0.40's. 


Bullboard Posts